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Summary
AIMS OF THE STUDY: To assess the health-seeking be-
haviour, the patient delay (onset of symptoms to first con-
sultation) and the health system delay (first consultation
to start of tuberculosis treatment) among patients with pul-
monary tuberculosis (TB) diagnosed in Switzerland, and to
assess the predictors of the various types of delay.
METHODS: A survey among pulmonary TB patients was
carried out in six cantons, covering 42% of all pulmonary
adult TB cases notified in Switzerland. Data were collected
by collaborators of the cantonal lung associations in
charge of the follow-up of TB patients to investigate treat-
ment seeking behaviour and to establish various delays
and its predictors. Predictors of percentiles of delay (medi-
an and 75th percentile) were assessed using quantile re-
gression.
RESULTS: Among 252 eligible patients, 162 patients
could be interviewed. Of these, 20.4% were born in
Switzerland. Cough as a symptom was mentioned by 76%
of the interviewed patients. Almost half of the 162 patients
(46%) consulted first a general practitioner in an ambula-
tory care setting and 26% approached a hospital first. The
median delay between symptom onset and first healthcare
contact (patient delay) was 5.2 weeks, which is slightly
longer than findings in other low prevalence countries. The
interquartile range was 1.6 to 14.2 weeks. The median de-
lay between first consultation in Switzerland and the start
of TB treatment (health system delay) was 2 weeks. The
interquartile range was 0.6 to 7.1 weeks.
: There were no clear predictors of patient delay. The main
predictors of a longer median health system delay were
the presence of fever (1.6 weeks, 95% confidence interval
[CI] 0.5 to 2.6 weeks), having visited first a general practi-
tioner or a paediatrician (1 week, 95% CI 0.1 to 1.9 weeks)
and having seen three or four doctors before beginning
TB treatment (2.9 weeks, 95% CI 0.7 to 5.1 weeks). A
clear predictor of a shorter median health system delay
was having undergone an X-ray at the first consultation
(−2.9 weeks, 95% CI −4.8 to −0.9 weeks). Marginally sig-
nificant for shorter delay was male sex (−2.6 weeks, 95%
CI −5.4 to 0.1 weeks).
CONCLUSIONS: No predictor of patient delay was found
among the variables collected. For one fourth of the pa-
tients, the health system delay was longer than 7 weeks.
General practitioners are commonly approached first, and
they have to consider TB, also for patients not considered
at high-risk for TB.
Keywords: tuberculosis, delay, patient delay, health sys-
tem delay, predictors, Switzerland
Introduction
Tuberculosis (TB) is a rare disease in Switzerland, with
a constant decline in the number of notified cases up to
2007 [1]. Since then, the number of cases has been oscil-
lating between 485 and 630 per year, with some indication
of an increase from 2014 to 2016 [2]. For 2015, the World
Health Organization reports for Switzerland an incidence
rate of 7.4 per 100,000 population, similar to that of neigh-
bouring countries (5.8 per 100,000 in Italy, 7.6 in Austria,
8.1 in Germany and 8.2 in France) [3].
As TB is an airborne transmissible disease, early diagnosis
and appropriate treatment are important to reduce trans-
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mission of bacteria to the population. TB is often a slowly
progressive disease, and therefore there may be a delay be-
tween the beginning of the symptoms, the first medical vis-
it and the initiation of adequate treatment. This in turn de-
pends on the awareness and sensitivity of the patients with
symptoms, the ease of access to health care, and the knowl-
edge level and alertness of the healthcare providers. Recent
studies among TB patients in Europe have found a patient
delay (the time from symptom onset to the first visit to a
doctor) of between 2 and 4.5 weeks, and a health system
delay (the time from the first medical visit to the start of
TB treatment) of between 2 and 5.5 weeks [4–9].
To better understand the experiences of pulmonary TB pa-
tients in Switzerland before appropriate treatment is pro-
vided, the Federal Office of Public Health of Switzerland
commissioned the Swiss Tropical and Public Health Insti-
tute to perform two studies: (i) a study on the knowledge
level of general practitioners (family doctors) in Switzer-
land regarding tuberculosis and its management and (ii) a
study of the experiences of patients with pulmonary TB,
with a focus on the various delays between symptom onset
and start of TB treatment (TB delay study). The first study,
published in 2016, identified some uncertainties among
general practitioners, mostly about the proper use of vari-
ous diagnostic tests and on how to correctly conduct a con-
tact investigation [10]. This paper presents the TB delay
study. The main objectives of the study were: (i) to assess
the various delays (onset of symptoms to first consultation
and first consultation to start of TB treatment); and (ii) to
establish the predictors of the various types of delay.
Methods
Ethics approval
The study was approved by the ethics commission of
Northwest- and Central Switzerland (Ethikkommission
Nordwest- und Zentralschweiz; reference number EK:
328/13).
Study scope and population
We carried out a survey in the cantons Aargau, Baselland,
Geneva, Solothurn, Vaud and Zurich from November 2014
to June 2016 among patients with pulmonary tuberculosis.
It was not feasible to include all cantons, thus four Ger-
man-speaking and two French-speaking cantons were se-
lected, all of them with a high number of TB cases com-
pared with most other cantons. Patients were eligible if
they had been diagnosed with smear- or culture-positive
pulmonary tuberculosis and were at least 18 years old. All
patients with residency in any of the six cantons and noti-
fied to the cantonal lung associations through the cantonal
medical officer (Kantonsarzt) were included in the study.
For the patient interview, healthcare professionals of the
cantonal lung associations, mandated by the cantonal
health officer for the ambulatory care of TB patients and
for contact investigations, approached the patients. The pa-
tients from Baselland were interviewed by the lung asso-
ciation Solothurn. With a few exceptions (mostly patients
of very high age), all registered TB patients were invited
by the healthcare providers of the lung associations to par-
ticipate, and asked to provide written consent. The patients
were interviewed face-to-face, at home or in an ambulatory
care setting, between November 2014 and July 2016. Inter-
viewers (mostly trained nurses) were experienced in taking
care of TB patients. Given that some patients were not flu-
ent in the local language of their canton, professional inter-
preters were solicited when required.
The paper-based questionnaire (available in German,
French and English) consisted mainly of closed questions
covering the following areas: (i) demographic data about
the patient; (ii) beginning of the symptoms suggestive of
TB; (iii) initial and follow-up contacts with the healthcare
system; and (iv) personal situation when the symptoms be-
gan and when a health care provider was approached (the
questionnaire is provided in appendix 1).
TB delay was captured through questions regarding the
date of the start of symptoms (or the date when a healthcare
provider was consulted if the health seeking was not trig-
gered by symptoms), the date when the patient realised that
a medical visit was needed (for establishing the “realisa-
tion delay”), the date of the first contact with the healthcare
system (usually a doctor), and the date of the start of TB
treatment.
Definition of the delays
For this study, the following concepts of delay were used:
– Patient delay: time from symptom onset to the first
medical visit to a doctor
– Within patient delay, two phases were differentiated: (i)
the “realisation delay”: time from symptom onset to re-
alisation/awareness that a healthcare provider should be
consulted and (ii) “access delay”: time from the realisa-
tion that a healthcare provider should be consulted to
the first meeting with a healthcare provider.
– Health system delay (also called provider delay or doc-
tor delay): the time from the first medical visit to the
start of TB treatment.
– Total delay: the time from symptom onset to the start of
TB treatment.
Data management and data analyses
The healthcare professionals of the participating lung as-
sociations wrote the answers provided by the patients dur-
ing their interviews on a paper questionnaire form. Data
from these forms were independently double entered into
EpiData (version 3.1) and inconsistencies were addressed.
Datasets were exported into STATA (Version 14.0) to carry
out the statistical analyses.
The main focus of the data analysis was to study the pre-
dictors of the various delays (patient delay, including reali-
sation delay and access delay, and the health system delay).
After careful deliberation, we decided to assess predictors
of delay using quantile regression. Whereas classical linear
regression is used to model the mean of a quantitative
outcome variable, quantile regression allows modelling of
specific percentiles instead. We focused on the median
(P50) and the 75th percentile (P75) of the respective out-
come variable (i.e., one of the delay times in our case).
These models have the following forms:
P50 = β0 + β1 ∙ x1 + β2 ∙ x2 + ⋯ + βp ∙ xp
P50 = β0 + β1 ∙ x1 + β2 ∙ x2 + ⋯ + βp ∙ xpwhere x1,
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x2, …, xp are the values of the independent variables con-
sidered in the model.
All models included the core variables: sex, age, canton
of residence, education level and indicator variables for
“Swiss citizenship”, “smoker’s cough” and “status of asy-
lum seeker”. These core variables were chosen on the basis
of a review of the relevant literature and on our understand-
ing of the situation of TB health seeking in Switzerland.
Additional variables were added to the core model one by
one.
In this article, we present results for median delay times,
whereas results for the 75th percentile can be found in ap-
pendix 2.
Sex, age, canton of residence and nationality were assessed
for all eligible and registered patients, including the non-
participants. This enabled analyses adjusting for self-se-
lection bias using inverse probability weighting (IPW).
This method consists of giving observations from under-
represented groups higher weights and observations from
over-represented groups lower weights in the analyses. The
weight of an observation is defined as the inverse of the
respective person’s probability of accepting participation
in the study, and these probabilities are estimated using
a logistic regression model for the outcome “acceptance
of participation”. All gathered variables, namely, age, sex,
nationality (Swiss vs non-Swiss) and canton of residence,
were included into this model. Results of the weighted
analyses (IPW) are presented in appendix 2.
Results
In the six cantons covered by the study, 252 patients were
registered between November 2014 and June 2016. This
represents 42% of all pulmonary TB cases (n = 601 [11])
aged 18 years and above registered in Switzerland over the
study period. Among the 252 eligible cases, 162 could be
interviewed (participation rate of 64%, ranging from 56%
in the canton of Geneva to 93% in canton Aargau). Most of
the others refused, some were not asked to be interviewed
(mostly due to old age, psychosocial challenges or poor
health status), and two died. Figure 1 presents the number
of patients interviewed and the number of patients includ-
ed in the various analyses.
Patient characteristics
The median age of the 162 participants was 35 years; 66%
were male. Only 20.4% (33/162) were born in Switzerland.
Among the 129 foreign-born patients (79.6%), 67 were
working or living in Switzerland (15 of them had in the
meantime acquired Swiss citizenship) and 62 were asylum
seekers. Among the 62 asylum seekers, 22 had been grant-
ed refugee status; for 33, this was pending and for 7, the
request for asylum had been rejected.
Among the non-Swiss patients, the most common coun-
tries of origin were Eritrea (n = 24), Portugal (n = 9), China
(all from Tibet) (n = 7), Afghanistan (n = 6), Italy (n =
6), Germany (n = 4) and Somalia (n = 4). Among the six
participating cantons, Geneva had the highest rate of non-
Swiss and male participants (90.9 and 78.8%, respectively,
of the 26 participants).
Sixty percent of the interviews were conducted in either
German (30.3%) or French (29.6%), and 8% in English.
Fifty-two interviews (32.1%) were conducted in other lan-
guages (see appendix 3), 49 of them with the help/inter-
vention of an interpreter.
The median age of the 90 registered cases who did not par-
ticipate in the study was 41 years, significantly higher than
the median age of the participants (p = 0.02). Among those
included, 9.3% (15/162) were older than 70 years: 13 of
the 48 participants with Swiss citizenship (27.1%) versus 2
of the 114 non-Swiss participants (1.8%) (p <0.001). One
third of the patients born in Switzerland (11/33) were older
than 70 years.
Figure 1: Number of patients included in the study and the various analyses.
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Table 1 presents the patient characteristics in detail.
Patients’ knowledge about and experience with TB
The study participants were asked about their knowledge
on TB at the moment they had realised that they should vis-
it a doctor. Approximately three quarters knew that TB is
an infectious disease, that TB can kill and that TB can be
treated (table 2).
Symptoms related or believed to be related to tubercu-
losis
The main complaint was cough, mentioned by 75.9% of
patients. Other symptoms were less frequent (fig. 2).
Among the 39 patients (24.1%) without cough, 9 (5.6% of
the 162) had none of the other five symptoms commonly
associated with tuberculosis (haemoptysis, tiredness,
weight loss, sweating, chest pain). Four patients stated that
they did not experience any symptom at all during the time
before the start of TB treatment; they had a medical con-
sultation because it had been planned in advance, for ex-
ample, in the frame of a routine medical visit.
Comorbidities
The most commonly identified comorbidities were smok-
er’s cough (14.8%) and chronic obstructive pulmonary dis-
ease (COPD) / bronchitis / asthma (11.1%). Seven patients
mentioned alcoholism and six the use of illicit drugs. Five
of the 162 TB patients were reportedly infected with the
human immunodeficiency virus (HIV).
Table 1: Characteristics of the 162 tuberculosis patients interviewed.
Patient characteristics Number Percentage
(of 162)
Sex
Male 107 66.0%
Female 55 34.0%
Age Median age was 35 years
18 to 29 years 56 34.6%
30 to 44 years 57 35.2%
45 to 59 years 21 13.0%
60 to 74 years 16 9.9%
75 to 90 years 12 7.4%
Education
0 to 5 years 29 17.9%
6 to 9 years 56 34.6%
At least 10 years 74 45.7%
Not clear 3 1.9%
Country of birth
Switzerland 33 20.4%
Elsewhere in Europe 21 13.0%
Other 108 66.7%
Nationality at time of interview
Swiss 48* 29.6%
Other European country 38 23.5%
Other 93† 57.4%
Occupation when patient went to doctor for the first time
Employed 55 34.0%
In asylum-seeking process 41 25.3%
Retired 24 14.8%
Jobless 14 8.6%
Receiving social security pension 12 7.4%
In school / training 9 5.6%
Other (e.g., traveller) 7 4.3%
* 13 of with a second nationality †The total is higher than 162 because of 17 participants with two nationalities.
Table 2: Knowledge of and experience with tuberculosis (TB).
Knowledge/experience Among the 162 participants Among the 33 born in
Switzerland
Among the 129 not born
in Switzerland
n % % %
TB is an infectious disease 122 75.3% 84.8% 72.9%
TB can be deadly 115 74.7% 78.8% 69.0%
TB can be treated 121 71.0% 81.8% 72.9%
Knew at least one person who had had TB 78 48.1% 39.4% 50.4%
Knew at least one person who had died of TB 27 16.7% 9.1% 18.6%
Patient had had TB before the current TB episode 15 9.3% 0% 11.6%*
* This difference was statistically significant (p = 0.042, Fisher’s exact test, two-tailed).
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Help-seeking behaviour
For most participants, the first medical consultation with
a medical doctor took place in Switzerland; only 8% had
first visited a doctor outside Switzerland (11 of these 13
were not Swiss). Almost half of the patients first visited a
general practitioner in an ambulatory care setting (table 3).
During this first consultation, 90% underwent a physical
examination and 78.3% blood testing. For 58.6% of the pa-
tients, a chest X-ray was taken during the first consultation
or a referral for an X-ray examination ordered. The three
most common outcomes of this first consultation were: (i)
prescription of medicines other than TB medication (for
57.6%); (ii) agreement to a second visit (for 36.1%) and
(iii) referral to a hospital (for 34.1%).
Approximately one third of the patients (35.2%) had only
one or two doctor appointments in Switzerland during the
time from onset of symptoms to the start of TB treatment;
44.4% had three, four or five appointments and 16% had
more than five appointments (for 3.7% the number was not
clear).
Patient delay
The patient delay estimate was based on the reports of 128
patients. For another 34 patients, estimating the patient de-
lay was not applicable: 4 patients had no symptoms, for
7 patients the data were incomplete and 23 patients went
to see a doctor because this had already been agreed upon
some time previously or because a medical visit was part
of an on-going process (mostly among asylum seekers).
The median delay between symptom onset and first health-
care contact was 5.2 weeks (mean 2 weeks). The interquar-
tile range was 1.6 to 14.2 weeks. The median delay ranged
from 3 weeks in the canton of Zurich to 9.4 weeks in
the canton of Geneva. Overall, the differences between the
cantons were not statistically significant. However, when
Geneva was compared with the other cantons, the patient
delay was significantly longer in Geneva (p = 0.009;
Wilcoxon rank sum test).
The median realisation delay was 4.1 weeks; one quarter
had a realisation delay of 14 weeks or longer. The median
access delay (among the 115 patients with data related to
access delay) was 0 days (mean 1.7 weeks). In other words,
many patients immediately accessed healthcare once they
concluded that they needed health care. One quarter of the
patients had an access delay of 1.3 week or longer.
Health system delay
Health system delay was estimated for 154 patients; data
from eight patients were incomplete. The median delay be-
tween first consultation in Switzerland and the start of TB
treatment was 2 weeks (mean 6.3 weeks). The interquartile
range was 0.6 to 7.1 weeks. The median delay was shortest
in canton Aargau (1.2 weeks) and longest in canton Vaud
(3.3 weeks) (difference statistically not significant).
Total delay
Total delay was estimated for 132 patients. The median de-
lay between symptom onset and the start of TB treatment
was 11.5 weeks (mean 22.6 weeks). The interquartile range
Figure 2: Frequency of symptoms among the 162 tuberculosis patients.
Table 3: Place of the first consultation in Switzerland.
Place of the first consultation n %
Primary care physician’s office 74 45.7%
Hospital 42 25.9%
Emergency / walk-in clinic 14 8.6%
Doctor of the asylum-seeking centre / doctor of an institution 10* 6.1%
Practice of a paediatrician or pulmonologist 4 2.5%
Other 18 11.1%
* Nine refugees and one prisoner
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was 5.6 to 22.5 weeks. The median delay was shortest in
canton Baselland and longest in canton Geneva (no statis-
tically significant differences).
Figure 3 presents an overview of the various delays.
Predictors of patient delay and health system delay
The quantile P50 regression analysis showed that there
were no predictors of patient delay (appendix 2 presents
P75 regression findings, with and without IPW, where
some statistically significant predictors were identified).
When the 16 patients who had a patient delay of 0 days
were excluded from the analysis, the results were un-
changed. Similarly, there were no statistically significant
predictors for realisation delay nor for access delay (when
applying P50 without IPW).
The symptom fever was a predictor of a longer health sys-
tem delay: the estimated time span until 50% of the pa-
tients with fever had started TB treatment after the first
consultation was 1.6 weeks longer (95% confidence in-
terval [CI] 0.5 to 2.6 weeks) than the corresponding time
span for the patients without fever (p = 0.004). Surprising-
ly, even patients who had fever and sweating and weight
loss (n = 45) had a longer health system delay than patients
without fever (p = 0.003). The estimated health system de-
lay until 50% of the patients that had gone for the first
consultation to a general practitioner or paediatrician was
1 week longer (95% CI 0.1 to 1.9 weeks) than the corre-
sponding time for the patients not having gone to a general
practitioner or paediatrician as first consultation. Not sur-
prisingly, patients who visited three or four doctors during
their journey from first consultation to start of TB treat-
ment had a longer health system delay than patients who
visited only one or two doctors for the same health trou-
ble. Predictors of a longer delay with borderline signifi-
cance (p-values between 0.051 and 0.098) were living in
canton Vaud compared with living in Aargau, living in can-
ton Zurich compared with living in Aargau, the symptom
chest pain and comorbidity COPD.
A strong predictor for a short health system delay was hav-
ing undergone an X-ray at the first consultation: the time
until 50% of the patients that had an X-ray at their first
consultation began treatment was 2.9 weeks shorter (95%
CI −4.8 to −0.9 weeks) than the time until 50% of the pa-
tients without an X-ray at the first consultation began treat-
ment. Being male was a predictor for a short health system
delay with borderline statistical significance: being male
was associated with a health system delay shorter by 2.6
weeks (95% CI −5.4 to 0.1 weeks). Table 4 presents de-
tails; it also presents predictors at the level p <0.1.
Predictors of the total delay
Table 5 presents the predictors of total delay: there was
no predictor of a long total delay. There was one statisti-
cally significant predictor of a short total delay: the time
until 50% of the patients who had an X-ray at their first
consultation began treatment was 5.5 weeks shorter (95%
CI −10.8 to −0.2 weeks) than the time until 50% of the
patients without an X-ray at the first consultation began
treatment. Predictors of a short total delay with borderline
statistical significance were having submitted a sputum
sample at first consultation and having had a comorbidi-
Figure 3: Overview of the various delays (median) and their extent.
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ty other than COPD/bronchitis/asthma, diabetes mellitus,
cancer, alcoholism, smoker’s cough, drug addiction or HIV
(see table 5).
Discussion
The patient delay (median 5.2 weeks) is slightly longer
than the patient delays reported from some publications
from low-prevalence countries (2 weeks in France [5], 4
week days in Norway [9], 4.3 weeks in Qatar [12]), but
compares favourably with findings from other studies (9
weeks in East London [13], 6.1 weeks in Spain [14]). This
delay is mainly due to the slowly progressive nature of
TB and depends on individual factors such as sensitivity to
health trouble.
To our knowledge, this is the first study reporting sepa-
rately the “realisation delay” and the “access delay”, de-
fined as the delay between the awareness of a health trou-
ble that needs medical consultation and the time of the first
medical visit, as a proxy for access to health care. It is re-
assuring to note that this access delay is short (median 0
days, mean 1.7 weeks), indicating that health care is readi-
ly available for all patients living in Switzerland, whatever
their origin or legal status, with some differences between
the cantons.
The health system delay (median 2 weeks, mean 6.3
weeks) seems to be shorter than in other low-prevalence
countries (median 3.6 weeks in France [5], 4.7 weeks in
Norway [9], 4.9 weeks in England [7]), but it has to be
noted that for one quarter of the patients the delay was
longer than 7 weeks, which may be surprising in a country
where diagnostic equipment is readily available. This long
delay may be due to the fact that half of the patients first
visited a general practitioner, who may have no or limit-
ed experience with TB, and that approximately half of the
patients had to visit three or more doctors to have a fi-
nal diagnosis established. Another explanation may be that
often patients with tuberculosis have symptoms compat-
ible with common diseases (e.g., influenza, exacerbation
of COPD, pneumonia) though the prominence of tiredness
and weight loss (see fig. 2) does not support this expla-
nation. The evaluation of the health system delay did not
include the asylum seekers who were submitted to imme-
diate medical examination after entry in Switzerland, for
whom the delay may have been influenced by travel con-
ditions and access to care prior to the immigration.
This survey found that the health system delay, i.e., the de-
lay between the first medical visit and the initiation of TB
treatment, was longer for patients with fever, for those who
first went to see a general practitioner or paediatrician, for
those who did not have a chest X-ray at first consultation
and for female patients.
The literature reports many factors associated with delays
in realising that symptoms may be due to TB, delay in ob-
taining an appointment at a healthcare structure and delays
between the first medical visit and the initiation of treat-
ment. Some factors seem to be similar whatever the local
prevalence of TB, and are therefore independent of the de-
gree of familiarity of the medical professionals with TB,
whereas others differ between the regions of the world.
Furthermore, some factors seem to be associated with
longer delays in some regions of the world and with short
delays in others. According to a large meta-analysis pub-
lished in 2008, chronic cough, female sex, low awareness
of TB, limited access to health care and history of immi-
gration are the most common risk factors for a prolonged
total delay [15]. The association of fever and especially of
the combination of fever, sweating and weight loss with
a longer health system delay, which we have observed, is
surprising and was not reported in other studies. It may be
due to the fact that fever is a common symptom in many
minor infectious diseases, particularly during winter, and
Table 4: Predictors of health system delay (P50 quantile regression model; n = 154).
Predictor Effect* (95% CI) p-value
Predictors of a long delay
Fever 1.6 (0.5 to 2.6) 0.004
First consultation at a general practitioner or paediatrician 1.0 (0.1 to 1.9) 0.024
3 to 4 doctors seen until start of TB treatment (versus only 1 or 2) 2.9 (0.7 to 5.1) 0.01
Living in VD (compared with AG) 1.9 (−0.004 to 3.8) 0.051
Living in ZH (compared to AG) 1.7 (−0.2 to 3.7) 0.083
Chest pain 1.8 (−0.2 to 3.7) 0.071
Comorbidity COPD 3.7 (−0.7 to 8.0) 0.098
Predictors of a short delay
X-ray was taken at first consultation −2.9 (−4.8 to −0.9) 0.004
Male sex −2.6 (−5.4 to 0.1) 0.060
AG = canton Aargau; CI = confidence interval; COPD = chronic obstructive pulmonary disease; TB = tuberculosis; VD = canton Vaud; ZH = canton Zurich All estimates were
obtained from models which (also) included sex, age, nationality, canton of residence, education level and indicator variables for “Swiss citizenship”, “smoker’s cough” and “status
of asylum seeker”. * Effect expressed in weeks
Table 5: Predictors of total delay (P50 quantile regression model; n = 132).
Predictor Effect* (95% CI) p–value
X-ray examination at first consultation –5.5 (–10.8 to –0.2) 0.043
Sputum submitted at first consultation –5.0 (–10.4 to 0.3) 0.064
Co-morbidity other than COPD/bronchitis/asthma, diabetes mellitus, cancer, alcoholism, smoker’s cough, drug
addition, HIV†
–6.9 (–14.3 to 0.6) 0.071
CI = confidence interval; COPD = chronic obstructive pulmonary disease: HIV = human immunodeficiency virus * Effect expressed in weeks. † Mostly conditions occurring in only
1 patient; 3 patients mentioned hepatitis B and 2 mentioned hypertension.
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is thus considered as a self-limiting symptom not requir-
ing further medical examinations. However, the increased
health system delay among patients with fever and sweat-
ing and weight loss, a combination of symptoms which
should create strong suspicion that the patient may have
TB, is worrying.
The total delay observed in this study is comparable with
the result of a prior study conducted in Geneva between
1999 and 2003 [16].
The health system delay was shorter among foreign-born
than Swiss patients (though this was only seen when ap-
plying the P75 regression); this may reflect a higher degree
of suspicion of TB among the doctors when a foreign-born
person has symptoms suggestive of TB.
Surprisingly, several studies mention the fact that the oc-
currence of haemoptysis, reflecting the presence of extend-
ed and severe disease with tissue destruction, may be asso-
ciated with a prolonged patient delay [17], which did not
seem to be the case in this study.
The access delay, i.e., delay in obtaining an appointment
at a healthcare facility (usually a general practitioner or
a hospital), was rather short in this study, as distance to
the facilities do not play a major role in Switzerland com-
pared with large countries or developing countries with
scarce availability of health structures [18, 19]. Financial
constraints play a minimal role as all persons living in
Switzerland are covered by a mandatory health insurance
scheme (with the exception of undocumented migrants and
tourists).
Cough is the main symptom of pulmonary TB, but also of
many other medical conditions and the vast majority of pa-
tients with chronic or persistent cough have a disease other
than TB, particularly in regions where TB is a rare disease
[20]. For cost containment reasons, doctors are expected to
use diagnostic procedures with caution. It is, therefore, not
surprising that in most patients with cough a radiographic
examination or a sputum test is not performed at the first
visit, particularly if they are smokers. This translates in-
to a risk factor for a prolonged health system delay. The
correct balance should be a high level of suspicion of TB
in the presence of additional risk factors for TB, such as
a history of contact with TB, origin from a region with
a high TB prevalence, association with other suggestive
symptoms and progressive nature of the complaints. In sit-
uations where the likelihood of TB is elevated, perform-
ing a radiographic examination of the chest and – if ab-
normal – ordering a sputum examination is the appropriate
procedure [21–23]. The Federal Office of Public Health of
Switzerland has developed an automated, web-based inter-
view tool for identifying people at high risk of having TB
(www.tb-screen.ch), a tool that can also be used by general
practitioners. Not performing the appropriate examination
in due time may result in patients visiting the same facility
repeatedly or searching for help at another healthcare insi-
tution, thus prolonging the duration of transmission of my-
cobacteria [7, 12, 24].
Swiss-born patients tended to have a shorter access delay
but had a longer health system delay than foreign-born pa-
tients (in P75 results). A similar observation has also been
made in Italy, where Italian-born patients had a shorter pa-
tient delay than foreign-born migrants (median 0.4 vs 2
weeks) but a longer health-care delay (median 8.6 vs 2.6
weeks) [25]. This can be because Swiss citizens have bet-
ter knowledge of available health services and are used to
rapidly visiting a general practitioner in the event of health
trouble, but that doctors rarely consider TB as a possible
cause of cough, fever and fatigue among Swiss citizens,
particularly as they seldom have the opportunity to detect
TB in the resident population.
A weakness of this study is the incomplete recruitment
of patients, some of whom were excluded for individual
reasons (high age, difficult communication) or refused to
participate. For these reasons, we performed a sensitivity
analysis using inverse probability weights (IPW) to adjust
for differences in participation rate associated with base-
line characteristics of the patients. This resulted in effect
estimates that were for the most part similar. Although
this argues against the presence of major participation bias,
some bias associated with unobserved characteristics of
nonparticipants may have remained.
Patients were interviewed while still on treatment. Howev-
er, the questions relating to delay referred to events in the
past. Therefore, some recall bias cannot be excluded. Re-
call bias could not be addressed in the analysis.
Another limitation of the study is that patients from only
six cantons were recruited. Thus, some findings may not be
representative of the situation in Switzerland as a whole.
For instance, in this study, there were only four patients
from Somalia. Had canton Ticino also been included in the
study, the number of patients from Somalia (and from oth-
er African countries) would have been higher as many asy-
lum seekers from Somalia enter Switzerland through can-
ton Ticino.
As TB is a slowly progressive disease, some delay in its
diagnosis and treatment is unavoidable, but should be kept
to a minimum. Easy access to health care for all should
be granted, including migrants, underserved populations,
patients without insurance coverage or patients with addi-
tional comorbidity. Transmission of medical information,
including for cross-border migrants, is necessary for the
adequate management of patients with unstable residen-
cy [26, 27]. Continuous medical education and regular re-
minders for general practitioners (including paediatricians)
working in the ambulatory care setting, who may be the
first to examine patients with symptoms suggestive of TB,
is necessary for avoiding undue delays in diagnosis. In
many countries, TB is the disease of limited, hard-to-reach
populations. Interventions to facilitate the access of these
vulnerable groups to health care, including efficient admin-
istrative procedures between facilities/shelters for arriving
asylum seekers and appropriate education of the healthcare
workers, may decrease the delay and associated transmis-
sion of the disease [28].
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Appendix 1
The questionnaire
Appendix 2
Predictors of patient, health system and total
delay – P50 and P75, without and with IPW
Appendix 3 Languages other than German, French or
English in which the interviews were conduct-
ed
The appendices are available as separate files for down-
loading at https://smw.ch/en/article/doi/smw.2018.14659/
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